摘要
Abstract
Objective:To investigate the effects of Trastuzumab combined with Paclitaxel and Epirubicin neoadjuvant chemotherapy on immune function,estrogen receptor(ER)and progesterone receptor(PR)in human epidermal growth factor receptor 2(HER2)positive breast cancer patients.Method:A total of 100 patients with HER2 positive breast cancer treated in Nanchang People's Hospital from December 2022 to December 2023 were selected and divided into two groups by random number table method,with 50 cases in each group.The control group was treated with Trastuzumab combined with Paclitaxel,and the observation group was treated with Trastuzumab combined with Paclitaxel and Epirubicin.The total effective rate of fever,immune function indexes(CD3+,CD4+,CD8+),the expression of ER and PR and the occurrence of adverse reactions between the two groups were compared.Result:The total effective rate of observation group was higher than that of control group,the difference was statistically significant(P<0.05).After treatment,CD3+,CD4+in observation group were higher than those in control group,CD8+was lower than that in control group,the positive rates of ER and PR were lower than those in control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:In the treatment of HER2 positive breast cancer patients,the application of Trastuzumab combined with Paclitaxel and Epirubicin neoadjuvant chemotherapy can promote the further improvement of clinical efficacy,help improve immune function,and reduce the positive expression of ER and PR,with ideal safety.关键词
曲妥珠单抗/紫杉醇/表柔比星/HER2阳性/乳腺癌/免疫功能Key words
Trastuzumab/Paclitaxel/Epirubicin/HER2 positive/Breast cancer/Immune function
